BXTAccelyon and Hitachi Medical Systems to support #TRexit
As the national campaign to eradicate traditional transrectal (TRUS) biopsies from the prostate cancer pathway gains momentum, BXTAccelyon is pleased to announce a training and promotion partnership with Hitachi Medical Systems UK.
Approaching 100 centres across England are now using the PrecisionPoint biopsy device, which allows transperineal (TP) biopsies to be conducted under local anaesthetic, helping to decrease infection rates and allowing for convenient, freehand access within an outpatient environment.
Last year Mrs May pledged £75 million funding for prostate cancer research, paving the way for breakthroughs in the diagnosis, treatment and prevention of this most prevalent cancer in men in the UK. The recent NICE Guidance on prostate cancer has made a positive recommendation that all patients referred with suspected prostate cancer should have an MRI scan before a decision is made on prostate biopsy. The NHS has become one of the first health care systems in the world to make such a recommendation.
This is greatly welcomed, as it is well recognised and documented that...